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Abstract
Mesenchymal stromal/stem cells (MSCs) are adult, self-renewable, multipotent cells that
can be isolated in various tissues, most commonly bone marrow (BM) and adipose tissue.
Because of their capacity for self-renewal and differentiation into tissues of mesodermal
origin and due to their immunomodulatory ability, MSCs are used in many preclinical
and clinical studies as possible new therapeutic agents for the treatment of a very broad
range of conditions, including heart, hepatic, and neurodegenerative diseases.
Whatever the tissue of origin or the clinical application, the MSCs must be expanded
in vitro to obtain sufficient cell numbers, also when multiple doses are needed.
The MSC manufacturing process for clinical use should comply with the principles of
Good Manufacturing Practice (GMP). This ensures that cell preparations are produced
and controlled, from the collection and manipulation of raw materials, through the
processing of intermediate products, to the quality controls, storage, labelling and
packaging, and release.
The application of GMP to manufacture medicinal products such as MSCs must
ensure that clinical trials are unaffected by inadequate safety, quality, or efficacy
arising from unsatisfactory manipulation of the cells.
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1. Introduction
Cell-based therapy has led to the development of new biological medicines to repair, replace,
or recover the biological function of damaged tissues and organs [1]. Among cell types used
for this purpose, human MSCs are considered as advanced therapy medical products (ATMPs)
and should be handled with appropriate controls to ensure their safety, quality, and efficacy
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as a final drug [2-3]. Mesenchymal stromal or stem cells have become of great interest in these
years in the field of regenerative medicine. They were initially referred to as multilineage
progenitor cells isolated and culture-expanded from adult human BM that, once in culture,
display a heterogeneous morphology and are capable of several subpopulations. They can be
expanded ex vivo and readily differentiate into mesodermal cell derivatives [4-5]. Horwitz and
the International Society for Cellular Therapy (ISCT) better defined them as “mesenchymal
stromal cells” (MSCs) [6].
The translation of research-based protocols into large-scale production of clinical-grade MSCs
requires careful analysis to identify and control all critical aspects: source of MSCs and raw
materials, culture media, supplements and disposable devices, and quality control tests [7].
The quality and safety of the cell preparations should be ensured by the implementation of a
quality system that guarantees the certification and traceability of every batch of material and
supply utilized for the procedures, correct utilization and cleaning of instruments, and the
locations necessary for stem cell manipulation. Facilities, isolation methods, seeding density,
growth factors, and chemicals can all influence the expansion potential and functional
properties of MSCs and should be considered throughout the production process. The
organization structure, qualification of staff with high levels of expertise, and the appropriate
equipment must be implemented in dedicated cleanrooms, currently named “Cell Factories,”
in compliance with current good manufacturing practice (GMP) standards. The application of
GMPs for aseptic production ensures the safety of the final cell therapy product. In 2008, the
International Society for Stem Cell Research released a set of recommended guidelines for the
development of stem cell–based treatments [8]. These recommendations are focused on the
risks involved with stem cell-based therapies, the voluntary informed consent, the patient
monitoring and adverse event reporting, and the equality of benefits of stem cell treatments.
2. Body
MSCs are adult, self-renewable, multipotent cells that can be isolated in various tissues, most
commonly BM and adipose tissue, but also in fetal tissues. Because of their capacity for self-
renewal and differentiation into tissues of mesodermal origin and due to their immunomo‐
dulatory ability, MSCs are used in many preclinical and clinical studies as possible new
therapeutic agents for the autoimmune or degenerative diseases treatment [9].
The MSC manufacturing process for clinical use should comply with the principles of GMP.
This ensures that cell preparations are produced and controlled, from the collection and
manipulation of raw materials, through the processing of intermediate products, to the quality
controls, storage, labelling and packaging, and release, according to the expected require‐
ments. During the whole production process, critical steps should be known and described. A
thorough risk analysis during all phases of production and control ensures a final product
with the expected quality, both for patients and for the regulatory authorities responsible for
the controls.
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2.1. MSC source
BM is still the most common source of MSCs. However, during the last two decades alternative
and more accessible tissue sources of MSCs have been identified.
MSCs have been isolated from fat, deciduous teeth, placenta, and umbilical cord blood,
showing comparable features to BM-derived cells [10]. In particular, fresh umbilical cord blood
is the third common source for isolating MSCs for clinical use, but the success rate in isolating
and further expanding MSCs depends on the volume of blood collected, the cell content, and
the time between collection and processing [12]. Related cell sources, including neonatal tissues
as amniotic fluid [11], placenta, and Wharton’s jelly (WJ), are interesting for their ability to
maintain their self-renewal capacity in vitro for a long period, showing a higher pluripotency
capacity as compared to BM-MSCs [13-15].
Adipose-derived stem cells (ASCs), if compared to BM MSCs, appear to have higher frequen‐
cies [16], higher proliferative capacity [16], and to be more stable in culture with a lower
senescence ratio [18]. The methods to isolate MSCs from lipoaspirates are standardized, even
with automated device to separate the tissue fraction of fat from the contaminating fluids [19].
ASCs have been tested in preclinical studies for the treatment of a variety of clinical conditions,
including Crohn’s disease, muscular dystrophy, myocardial infarction, spinal cord injury,
diabetes mellitustype1, breast reconstruction, and facial lipoatrophy [20].
2.2. MSC isolation and expansion
Several different methods for isolating MSCs have been described. After harvesting and, if
necessary as in case of fat, dissociation of tissue, MSCs could be seeded in flask with or without
gradient separation (Ficoll or Percoll), or after immunomagnetic enrichment [21]. The paper
of Mareschi showed that direct selection of MSCs from BM cells by adhesion to culture plastic
is a more advantageous method compared to MSCs obtained by gradient separation [22],
resulting also in a significantly higher level of HLA-DR [23]. Cell-plating density is a crucial
issue for MSC expansion. The use of very low density ensures a high proliferative potential
[24]. However, plating densities of 10 and 100 cells/cm2 did not produce any expansion [22].
Limiting the number of cell population doubling (CPD) to less than 20 avoids the progressive
senescence of expanded MSCs [23].
The use of reagents and supplements clinical grade and suitable for clinical application must
be considered for the in vitro expansion. Only few clinical grade reagents are commercially
available. Animal serum–free media, human serum, and other supplements of human origin
have been investigated. Human platelet lysate (HPL) has been demonstrated to be safe and
efficient as MSC culture supplement for robust MSC expansion and is now considered a good
fetal bovine serum (FBS) substitute [25-26]. In particular, Pathogen Inactivated HPL represents
a good GMP-compliant alternative to FBS [27].
2.3. MSCs as ATP
The European Regulation 1394/2007 introduced a new classification for cell therapy products
as medicinal products: the tissue-engineered products [28]. The Regulation defines Advanced
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Therapy Medicinal Products (ATMPs) as the gene therapy medicinal products, the somatic
cell therapy medicinal products, and the tissue-engineered products. These products have
specific pharmacologic, metabolic, and immunologic activities and the potential for treating a
variety of disorders. For these reasons, cellular products for ATMPs, prepared on a routine
basis, must meet the same stringent conditions required for drugs preparation and commer‐
cialization. In particular, they must be manipulated according to the GMP [29], and they
require preclinical testing in Good Laboratory Practice (GLP) [30-31] and clinical trials
conducted in Good Clinical Practice (GCP) before being commercialized [32].
MSCs represent a promising strategy for the development of new therapeutic strategies due
to the numerous applications proposed for their use [33]. Thanks to their intrinsic properties,
MSCs represent an attractive candidate for clinical applications [34-36]. As ATMPs, MSCs also
must satisfy all the above-mentioned requirements. The expansion protocol of MSCs for
clinical use should comply with the principles of GMP and take in account all critical steps of
the process. The quality and safety of the expanded MSCs must be maintained throughout
their production and quality control cycle, ensuring their safe use in the patient.The main
critical steps are the collection and manipulation of raw materials; the processing of inter‐
mediate products; the quality control tests; storage, labelling, and packaging; and release. The
validation of the process and a thorough risk analysis during all phases of production ensures
a final product with the expected quality, both for patients and for the regulatory authorities
responsible for controls [37].
2.4. GMP production of MSCs
MSCs represent a small fraction (0.001-0.01%) of the BM cell population; therefore, to obtain a
sufficient number of cells, they must be extensively ex vivo expanded.
One of the most significant properties that make MSCs a special device for cell-based thera‐
peutic approaches is their capability to expand in culture for several passages, without
compromising their pluripotent potential. MSCs can easily be expanded in culture thanks to
their capacity to adhere and proliferate maintaining their immunophenotypic characteristics
and functions as multipotent cells.
Several papers discussed in the last years the standardization of MSC culture conditions for
clinical use. As reported in the review by Ikebe, a total of 47 reports, describing MSC-isolation
methods, were found in literature published from January 2007 to 2013 [38].
The recent paper of Wuchter summarizes a consensus meeting between researchers, clinicians,
and regulatory experts on standard quality requirements for MSC production [39]. The
manufacture of sterile products, such as the ATMPs, is subject to special requirements in order
to minimize the risks of microbiological contamination. Maintaining the cells in culture for
several passages means subjecting them to the risk of contamination. The production process
of MSCs must be performed through a GMP protocol based on standard operating procedures
(SOPs) and documented according to GMP [40-41].
As mentioned in Annex 1 of GMP [42], the manufacture of sterile products should be carried
out in clean areas, laboratory named cleanrooms or cell factories, in which the concentration
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of airborne particulates is maintained and controlled. The key elements for designing a
cleanroom according to GMP requirements are the presence of HEPA filters, a room air change
rate of >20 per hour, the temperature and humidity control, and the air pressure differential.
The appropriate cleanliness standard can be maintained also through an appropriate man‐
agement of personnel, equipment, and materials. Premises and equipment should be designed
in order to minimize the accumulation of particles or microorganisms and to permit the
appropriate cleaning.
For the manufacture of sterile medicinal products, four grades can be distinguished:
• Grade C and D: clean areas for carrying out manufacturing steps not so critical.
• Grade B, for aseptic manipulation, is the background environment for grade A.
• Grade A, the local zone for high-risk operations, where the product is manipulated in an
open system. This condition is normally the laminar airflow biosafety cabinet.
Annex 1 also gives the recommended limits for microbiological monitoring of clean areas
during aseptic operations.
The concept of quality assurance and quality management are related to GMP requirements.
As reported in the Chapter 1 of GMP guidelines [43], the quality management covers all
matters, which individually or collectively influence the quality of a product.
A GMP-compliant quality system for the manufacture of medicinal products should ensure
that cell preparations are controlled, from the collection and manipulation of raw materials,
through the processing of intermediate products, to the quality controls, storage, labelling and
packaging, and release. During the whole production process, critical steps should be known
and described.
An appropriate quality system should cover all the following aspects:
• Roles and responsibilities. All the staff must be qualified and adequate. A qualified person
must certify the release of the medicinal products. Competencies, training and retraining
must be scheduled.
• Premises and equipments.
• Documentation.
• Raw materials, reagents, and suppliers.
• Quality control on intermediate products, in-process controls, and validations.
• Activities in outsourcing.
• Deviations, corrective/preventive actions, and change control.
• Storage, distribution, and labelling.
• Self-inspection and/or quality audits.
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Good documentation constitutes an essential part of the quality assurance system. Documents
may exist as paper-based or electronic format. The main documents, as required by GMP are
as follows:
• Site Master File, describing the Facility and the GMP activities.
• SOPs, detailed description of various processes.
• Working instructions, giving instructions on technical methods or activities.
• Records, registration, and reports, providing evidence of actions and steps.
• Certificate of analysis, providing a summary of quality control tests with the evaluation of
compliance of the product batch.
Approved procedures and instructions must be written in a clear and unambiguous form, and
the records must demonstrate that all the steps required by the defined procedures and
instructions were carried out by qualified operators.
2.5. Quality control
Quality Control is that part of GMP which is concerned with sampling, specifications, and
testing [44], also including outsourcing activities. The quality control process should be
validated to confirm that the analytical procedure employed for a specific test is suitable for
its intended use.
The recent paper of Torre and colleagues provides the minimal quality requirements for
the MSC production and its delivery for clinical use, to guarantee the safety of the final
cell therapy product. For this purpose, the document evaluates the most important steps
of  GMP-compliant  MSC production:  the  isolation and expansion process;  the  validation
phase of the process, including all quality controls for the characterization, functionality,
potency, and safety of MSCs; and the quality control at the batch release to guarantee the
safety of patient infusion [37].
An interesting approach to the GMP is validation. The production process should follow a
validation protocol, also considering instruments, supplies and reagents, and defining roles
and responsibilities of each step [45]. A validation protocol on a minimum of three expansion
procedures should be implemented to standardize the best culture condition and to demon‐
strate the safety and feasibility of the production protocol. It is a requirement of GMP that
manufacturers identify what validation work is needed to prove control of the critical aspects
of their particular operations. Significant changes to the facilities, the equipment, and the
processes, which may affect the quality of the product, should be validated. A risk assessment
approach should be used to determine the scope and extent of validation.
According to International Conference on HarmonizationQ2 (ICH Q2) Guidelines [45] and the
European (EU) Pharmacopoeia [47], the quality control (QC) process should be validated to
confirm that the analytical procedure employed for a specific test is suitable for its intended
use.
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Quality control analytical methods could be validated demonstrating the accuracy, the
specificity, the limit of detection, and the precision [45, 48-49].
In the validation phase of the process, additional assays to test immunomodulation, senes‐
cence, and genomic stability, clonogenicity should be carried out. Although tumour formation
during the validation process has not been reported in ongoing clinical trials using MSCs [50],
tumorigenesis and karyotype [23, 51] should be also tested during validation.
2.6. Clinical trials
Today, numerous MSC preparations from academic institutions and private companies are
being investigated. The review paper of Wang summarized the currently completed clinical
trials, registered with clinicaltrials.gov, using MSC to treat various diseases. The first clinical
trial using culture-expanded MSCs was carried out in 1995 and 15 patients became the
recipients of the autologous cells [52]. Since then, a great number of clinical trials have been
conducted to test the feasibility and efficacy of MSC therapy.
Today more than 450 clinical trials testing MSC are currently published on the international
registry www.clinicaltrials.gov, both recruiting or completed. Most trials are Phase I (safety
studies) or Phase I/II studies. Only a small number of these trials are in Phase III.
Expanded MSCs have been used to treat several diseases, from bone/cartilage disorder,
cardiovascular diseases, autoimmune diseases, and neurodegenerative disorders [12].
The experience of our group has been focalized to research a new possible strategy for
amyotrophic lateral sclerosis (ALS) aimed at cell replacement and neuroprotection.
The long term study of showed the safety of MSC transplantation in the central nervous system
during a follow-up of nearly 9 years, and is in support of applying MSC-based cellular clinical
trials to neurodegenerative disorders [53-55].
The application of GMP to the manufacturing of investigational medicinal products for clinical
trials must ensure that trial subjects are not placed at risk, and that the results of clinical trials
are unaffected by inadequate safety, quality, or efficacy arising from unsatisfactory manipu‐
lation of the cells. Annex 13 of GMP guidelines is the reference guide for this step [56].
3. Conclusion
Stem cell therapy has evolved over the past years, thanks to the great efforts of researchers to
define and implement new methods for MSC expansion, according to ATMP requirements.
The standardization of protocols and procedures, both for production and quality control,
within the collaboration of different groups, will lead to the definition of standardized
protocols to be considered during the process of expansion and release of MSC as ATMPs for
the application of clinical trials with MSCs.
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